完成性全胰切除术治疗残余胰腺孤立复发的临床结局
该回顾性研究纳入2009至2020年间93例初次胰腺切除术后残余胰腺孤立复发的胰腺导管腺癌患者,其中59例接受完成性全胰切除术,34例未接受。接受完成性全胰切除术者5年总生存率为61.7%、中位生存91.2个月,显著优于未手术者的22.3%和32.8个月(P < .001)。早期复发、肿瘤>4 cm及CEA升高为不良预后因素。
要点
- 完成性全胰切除术可使经选择的残余胰腺孤立复发患者获得有利的肿瘤学结局。
- 早期复发(初次术后1年内)、肿瘤>4 cm及CEA升高提示预后不良。
- 复发晚于1年、肿瘤<4 cm且肿瘤标志物稳定者可能更适合完成性全胰切除术。
核心结论
- 在残余胰腺孤立复发的胰腺导管腺癌患者中,完成性全胰切除术可能为经仔细选择的患者带来有利的肿瘤学结局。
研究设计与样本
- 回顾性研究纳入2009至2020年间93例初次胰腺切除术后残余胰腺孤立复发的胰腺导管腺癌患者,其中59例接受完成性全胰切除术,34例未接受。
主要发现
- 未接受完成性全胰切除术者初次胰腺切除术后5年总生存率为22.3%,中位生存32.8个月。
- 接受完成性全胰切除术者5年总生存率为61.7%,中位生存91.2个月(P < .001)。
- 早期复发者接受完成性全胰切除术的中位生存为33.5个月,晚期复发者为104.2个月。
- 早期复发是显著的不良预后因素(风险比6.684,95%置信区间2.474-18.062,P < .001),肿瘤>4 cm和CEA升高亦为不良预后因素。
临床怎么用
- 对残余胰腺孤立复发患者,可考虑完成性全胰切除术,但需仔细选择病例。
- 复发晚于1年、肿瘤<4 cm且肿瘤标志物稳定者可能从完成性全胰切除术中更多获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated the clinical features of patients with isolated recurrence of pancreatic ductal adenocarcinoma in the remnant pancreas after initial pancreatectomy. It specifically analyzed the postoperative and oncologic outcomes of patients who underwent completion total pancreatectomy to identify prognostic factors associated with 5-year survival. METHODS: A retrospective review was conducted on 93 patients with isolated recurrence of pancreatic ductal adenocarcinoma in the remnant pancreas after initial pancreatectomy between 2009 and 2020. Of these, 59 patients underwent completion total pancreatectomy, and 34 did not undergo completion total pancreatectomy. Clinicopathologic factors and overall survival were analyzed based on completion total pancreatectomy status. RESULTS: The 5-year overall survival after initial pancreatectomy for pancreatic ductal adenocarcinoma was 22.3% in the patients who did not undergo completion total pancreatectomy, with a median survival of 32.8 months. In contrast, patients who underwent completion total pancreatectomy exhibited a 5-year overall survival of 61.7% and a median survival of 91.2 months (P < .001). Among patients with early recurrence, those who underwent completion total pancreatectomy exhibited a median survival of 33.5 months. In contrast, patients with late recurrence showed a median survival of 104.2 months. Early recurrence after pancreatectomy was identified as a significant poor prognostic factor for survival (hazard ratio 6.684, 95% confidence interval 2.474-18.062, P < .001), along with tumor size >4 cm and elevated carcinoembryonic antigen levels. CONCLUSION: In the remnant pancreas, completion total pancreatectomy for isolated recurrence of pancreatic ductal adenocarcinoma may offer favorable oncologic outcomes in carefully selected patients-particularly patients with recurrence after 1 year, tumor size <4 cm, and stable tumor marker levels.
引用
- Park Y, Hwang DW, Lee JH, et al. Clinical outcomes of completing total pancreatectomy for isolated recurrence of pancreatic ductal adenocarcinoma in the remnant pancreas after initial pancreatectomy. Surgery. 2026. PMID: 41679124. doi:10.1016/j.surg.2026.110088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。